ERBB2 and intrahepatic cholangiocarcinoma: The upregulation of L1 cell adhesion molecule (L1CAM) enhances the activation of EGFR by interacting with EGFR, ERBB2, and ERBB3 and then increases resistance to cisplatin and proliferation of ICC cells through induction of its downstream signaling pathways including ERK and AKT [62,63].